Risk of Dementia after initiation of GLP-1 RA versus long-acting insulin in patients with type 2 Diabetes mellitus.
People with type 2 diabetes taking GLP-1 drugs showed 36% lower dementia risk than those on insulin, suggesting broader brain benefits.
GLP-1 RA use was associated with 36% lower overall dementia risk (HR 0.64, 95% CI 0.46–0.89) versus long-acting insulin in propensity-matched T2DM adults; liraglutide (HR 0.40) and dulaglutide (HR 0.42) showed significant protective effects specifically for unspecified dementia. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- Population-based retrospective cohort with propensity score matching
- Category
- cardiovascular_metabolic
- Maturity
- Validated
Why it surfaced
Large propensity-matched real-world cohort showing GLP-1 RA neuroprotection in T2DM. Adds to growing body of evidence for extrapancreatic GLP-1 RA benefits; dementia prevention is a massive unmet public health need. Well-designed observational study despite the need for RCT confirmation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.